CN111035801B - 银纳米团簇基壳聚糖水凝胶敷料及其制备方法和应用 - Google Patents
银纳米团簇基壳聚糖水凝胶敷料及其制备方法和应用 Download PDFInfo
- Publication number
- CN111035801B CN111035801B CN202010038788.0A CN202010038788A CN111035801B CN 111035801 B CN111035801 B CN 111035801B CN 202010038788 A CN202010038788 A CN 202010038788A CN 111035801 B CN111035801 B CN 111035801B
- Authority
- CN
- China
- Prior art keywords
- solution
- chitosan
- ncs
- silver
- mangiferin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0004—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0019—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
- A61L2300/104—Silver, e.g. silver sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
- A61L2300/626—Liposomes, micelles, vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Materials Engineering (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Abstract
本发明属于银纳米团簇基壳聚糖水凝胶敷料技术领域,公开了银纳米团簇基壳聚糖水凝胶敷料及其制备方法和应用。将银纳米团簇溶液(Ag NCs)和芒果苷脂质体溶液(MF‑Lip)混合搅拌,然后加入0.15‑3mL的1%(w/v)壳聚糖溶液,0.1‑3mL的3%(w/v)聚乙二醇溶液,混合搅拌,最后加入0.01‑0.3mL的2%(w/v)戊二醛搅拌5‑200min,停放30‑180min后成胶,得到Ag NCs@CH‑MF水凝胶敷料。本发明所提供的Ag NCs@CH‑MF水凝胶能够有效避免伤口感染,减少组织坏死,促进了组织修复再生,对于伤口愈合具有积极作用。
Description
技术领域
本发明涉及银纳米团簇基壳聚糖水凝胶敷料,特别涉及银纳米团簇基壳聚糖水凝胶敷料及其制备方法和应用。
背景技术
近些年,据世界卫生组织(WTO)数据显示,细菌造成的感染是欠发达国家和地区致病致死率最高的杀手之一。而主要用于杀菌和抑菌的抗生素,因其过度使用导致细菌的耐药性不断增加,对人类健康构成严重的威胁。虽然越来越多的天然抗菌化合物的抗菌研究已经逐渐取代使用频繁的合成抗生素,如壳聚糖抗菌剂、疫苗和噬菌体疗法,但天然化合物的抗菌活性较低,阻碍了它们在替代合成抗生素方面的实际应用。因此,开发出一种非抗生素类抗菌技术以及新的合成制剂成为各国生物医疗领域的研究热点。
水凝胶是一种性能独特的新兴高分子生物材料,能保持一定的形状,并吸收大量的水,可以做各种药物载体,比如现在被大量报道的壳聚糖水凝胶材料,其溶解性好,生物相容性和生物可降解性高,柔韧性、吸水性和透气性也很高,更容易被人体接受,基本没有过敏或者刺激的不良反应。但现有水凝胶本身仅具有三维结构和吸水作用,并不具有高效抗菌、抗氧化、促进组织修复再生等功能。
随着新型纳米材料的发展,涌现了一大批具有抗菌性能的纳米材料,已经报道的银纳米颗粒能够有效地控制创伤处细菌的生长,但银纳米颗粒也存在尺寸偏大,物理稳定性较差,易发生聚集、结块,且有一定毒性的缺点,限制了其临床应用。
超小尺寸的银纳米团簇(Ag NCs,<3nm)作为一类新兴的功能纳米材料备受关注。目前虽然已有研究人员在尝试将具有广谱抗菌性与高效杀菌的银纳米团簇材料作为一种新型的抗菌剂,添加到生物医药材料中,制备高效杀菌的银团簇基复合材料,但这些尝试并没有针对促进生物伤口修复过程及组织再生更新。综上所述,提供一种既能保证优异抗菌性能,又能减少炎症以及提高伤口愈合的复合敷料,对于医用临床具有重要意义。
发明内容
为了解决现有技术中银团簇基复合材料杀菌和提高伤口愈合能力不佳的技问题,本发明提供了银纳米团簇基壳聚糖水凝胶敷料的制备方法。
为了解决上述技术问题,本发明采用以下技术方案:
银纳米团簇基壳聚糖水凝胶敷料的制备方法,将银纳米团簇(Ag NCs)溶液和芒果苷脂质体溶液(MF-Lip)混合搅拌,然后加入0.15-3mL的1%(w/v)壳聚糖溶液,0.1-3mL的3%(w/v)聚乙二醇溶液,混合搅拌,最后加入0.01-0.3mL的2%(w/v)戊二醛搅拌5-200min,停放30-180min后成胶,得到Ag NCs@CH-MF水凝胶敷料;
所述银纳米团簇(Ag NCs)溶液和芒果苷脂质体溶液(MF-Lip)的总体积为0.01-3mL;
所述银纳米团簇(Ag NCs)的含银量为4.723mg/L,所述芒果苷脂质体溶液(MF-Lip)中含有芒果苷量1-500mg。
壳聚糖在医疗保健方面,表现出消炎抗菌和肌肤修复的功效,具有超强的吸附能力,已被用于伤口护理,但以壳聚糖这种天然聚阳离子多糖来替代抗生素,仍存在抗菌性不足的缺点,并且无法达到高效持续广谱抗菌。因此,本发明采用壳聚糖水凝胶作为载体,负载银纳米团簇及芒果苷,由于壳聚糖为聚阳离子物质,银纳米团簇与脂质体为负电性物质,通过静电作用结合,制备的复合水凝胶敷料兼具三者的性能,起到协同高效杀菌、抗炎作用;并且,制备得到的复合水凝胶敷料不仅具有可注射性,可针对多种复杂治疗环境,而且力学性能符合要求,能够有效避免伤口感染,减少组织坏死,促进了组织修复再生,对于伤口愈合具有积极作用。因此本发明得到的银纳米团簇基壳聚糖水凝胶敷料在烧伤、烫伤、皮肤创伤、慢性创口(如糖尿病及免疫功能缺陷)等治疗方面有着潜在的应用。
本发明所述1%(w/v)壳聚糖溶液没有具体限制,可以通过本领域常规方法制备,亦可市购,优选地,本发明是将1g壳聚糖溶于100mL的2%(w/v)乙酸溶液中加热溶解,然后加入氢氧化钠溶液中和得到的;所述壳聚糖为脱乙酰度为90%的壳聚糖。
本发明所述的银纳米团簇的制备方法为,将50mmol/L硫辛酸甲醇溶液1-5mL,超纯水3.3-33mL,20mmol/L硝酸银溶液0.2-20mL,100mmol/L硼氢化钠溶液0.05-5mL,混合搅拌,反应3h,离心得到银纳米团簇(Ag NCs)。
银纳米团簇(Ag NCs)由银核及外层配体组成,尺寸小于2nm,具有广谱杀菌性和生物相容性的特点,其理化性能与表面配体有关。而硫辛酸是一种既可以溶于水,也可以溶于脂肪的全能营养素,它参与每个细胞的能量释放工作,故本发明选择硫辛酸(DHLA)作为配体;但是,硫辛酸保护的银纳米团簇在复杂的生物体内的稳定性不好,容易发生分解,不利于长期的药物作用,本发明提供的壳聚糖水凝胶为具有三维交联网络结构的载体,壳聚糖为聚阳离子物质,银纳米团簇为负电性物质,壳聚糖水凝胶负载银纳米团簇,通过静电作用结合,使硫辛酸保护的银纳米团簇在复杂的生物体内的稳定性较差,容易发生分解的技术问题得到了解决,可使药物的作用得到充分的发挥。
本发明的芒果苷脂质体溶液(MF-Lip)的合成方法是采用薄膜分散法合成的,具体的方法为:将4-20重量份卵磷脂,1-15重量份胆固醇,0.1-10重量份的芒果苷(MF)溶解在溶剂中反应,反应后过滤,滤液为芒果苷脂质体溶液(MF-Lip)。
作为优选,所述溶剂为氯仿和甲醇混合物,所述氯仿和甲醇的体积比为1:1。
本发明的另一个目的是,提供采用上述制备方法制备得到的银纳米团簇基壳聚糖水凝胶敷料。
最后,本发明提供了所述银纳米团簇基壳聚糖水凝胶敷料在制备杀菌、抗炎症以及促进伤口愈合和组织修复再生复合材料中的应用。
由以上技术方案可知,本发明提供了银纳米团簇基壳聚糖水凝胶敷料及其制备方法和应用。银纳米团簇基壳聚糖水凝胶敷料起到协同高效杀菌、抗炎作用;银纳米团簇基壳聚糖水凝胶敷料不仅具有可注射性,可针对多种复杂治疗环境,而且力学性能符合要求,能够有效避免伤口感染,减少组织坏死,促进了组织修复再生,对于伤口愈合具有积极作用。
附图说明
图1为本发明所提供的水凝胶Ag NCs@CH-MF的合成示意图;
图2为本发明所提供的水凝胶Ag NCs@CH-MF的紫外可见吸收光谱图;
图3为本发明所提供的水凝胶Ag NCs@CH-MF的电镜扫描图;
图4为本发明所提供的大鼠伤口愈合情况及切片观察图;
图5为发明所提供的水凝胶Ag NCs@CH-MF的广谱抗菌性能测试的细菌平板图;
图6为本发明所提供的水凝胶Ag NCs@CH-MF的注射性能检测图。
具体实施方式
本发明公开了银纳米团簇基壳聚糖水凝胶敷料及其制备方法和应用,本领域技术人员可以借鉴本文内容,适当改进工艺参数实现。特别需要指出的是,所有类似的替换和改动对本领域技术人员来说是显而易见的,它们都被视为包括在本发明当中。本发明的方法及应用已经通过较佳实施例进行了描述,相关人员明显能在不脱离本发明内容、精神和范围内对本文所述的方法和应用进行改动或适当变更与组合,来实现和应用本发明技术。
为了使本领域技术人员能够更好的理解本发明,下面结合具体实施方式对本发明作进一步的详细说明。
对比例1
采用0.4mL 0.04mmol/L Ag NCs溶液(含银量为4.723mg/L),1.6mL超纯水,混合搅拌,得到含体积分数为0.2的Ag NCs(定义为0.2Ag NCs,团簇前的数代表体积分数,下同)。
对比例2
采用0.73mL超纯水,3%聚乙二醇溶液0.25mL,1%壳聚糖溶液1mL,搅拌30min,2%戊二醛溶液0.015mL,常温搅拌5min,静置100min成胶,得到1%壳聚糖水凝胶1%CH。
对比例3
采用0.73mL超纯水,3%聚乙二醇溶液0.25mL,2%壳聚糖溶液1mL,搅拌30min,2%戊二醛溶液0.015mL,常温搅拌5min,静置100min成胶,得到2%壳聚糖水凝胶2%CH。
实施例1
采用0.16mL Ag NCs溶液(含银量为4.723mg/L),0.57mL超纯水,混合搅拌20min,3%聚乙二醇溶液0.25mL,1%壳聚糖溶液1mL,搅拌30min,2%戊二醛溶液0.015mL,常温搅拌5min,静置100min成胶,得到Ag NCs@CH。
实施例2
采用0.32mL Ag NCs溶液(含银量为4.723mg/L),0.41mL超纯水,混合搅拌20min,3%聚乙二醇溶液0.25mL,1%壳聚糖溶液1mL,搅拌30min,2%戊二醛溶液0.015mL,常温搅拌5min,静置100min成胶,得到Ag NCs@CH。
实施例3
采用0.4mL Ag NCs溶液(含银量为4.723mg/L),0.33mL超纯水,混合搅拌20min,3%聚乙二醇溶液0.25mL,1%壳聚糖溶液1mL,搅拌30min,2%戊二醛溶液0.015mL,常温搅拌5min,静置100min成胶,得到Ag NCs@CH。
实施例4
采用0.4mL Ag NCs溶液(含银量为4.723mg/L),0.33mL超纯水,混合搅拌20min,3%聚乙二醇溶液0.25mL,2%壳聚糖溶液1mL,搅拌30min,2%戊二醛溶液0.015mL,常温搅拌5min,静置100min成胶,得到Ag NCs@2%CH。
实施例5
采用0.4mL Ag NCs溶液(含银量为4.723mg/L),0.33mL含芒果苷10mg的芒果苷脂质体溶液,混合搅拌20min,3%聚乙二醇溶液0.25mL,1%壳聚糖溶液1mL,搅拌30min,2%戊二醛溶液0.015mL,常温搅拌5min,静置100min成胶,得到复合水凝胶Ag NCs@CH-MF。
上述反应的原理示意图见图1所示。
对所述得到的水凝胶Ag NCs@CH-MF用紫外可见分光光度计进行成分分析,如图2所示,空白壳聚糖水凝胶1%显示出特征吸收峰为255nm附近,壳聚糖中添加银纳米团簇的水凝胶Ag NCs@CH,则多出一个430nm的Ag NCs特征吸收峰,而银纳米团簇基水凝胶负载芒果苷的Ag NCs@CH-MF,则又多了367nm的MF的特征吸收峰.通过图2表明,所制备的Ag NCs@CH-MF水凝胶中确实存在Ag NCs和MF两种物质。
并对水凝胶Ag NCs@CH-MF进行电镜扫描,扫描图见图3,图3(a)图为空白壳聚糖水凝胶的微观形貌,图3(b)为壳聚糖水凝胶负载银纳米团簇的微观形貌,图3(c)为壳聚糖水凝胶负载银纳米团簇和芒果苷的微观形貌。通过图3可知,由于亲水性银纳米团簇的加入,使水凝胶的孔径更为疏松,可以看到明显的孔,而疏水的芒果苷脂质体的加入使空隙致密,表现为孔和褶皱。
实施例6
采用1.5mL Ag NCs溶液(含银量为4.723mg/L),1.5mL含芒果苷1mg的芒果苷脂质体溶液,混合搅拌20min,3%聚乙二醇溶液3mL,1%壳聚糖溶液3mL,搅拌30min,2%戊二醛溶液0.3mL,常温搅拌100min,静置30min成胶,得到复合水凝胶Ag NCs@CH-MF。
实施例7
采用0.07mL Ag NCs溶液(含银量为4.723mg/L),0.08mL含芒果苷1mg的芒果苷脂质体溶液,混合搅拌20min,3%聚乙二醇溶液0.1mL,1%壳聚糖溶液0.15mL,搅拌30min,2%戊二醛溶液0.01mL,常温搅拌200min,静置120min成胶,得到复合水凝胶Ag NCs@CH-MF。
注:实施例中所用1%(w/v)壳聚糖溶液的制备方法:将1g壳聚糖(脱乙酰度为90%)溶于100ml的2%(w/v)乙酸溶液中加热溶解,然后加入氢氧化钠溶液中和得到的;所述芒果苷脂质体溶液的合成方法为,将12重量份卵磷脂,8重量份胆固醇,5重量份的芒果苷(MF)溶解在溶剂(体积比为1:1的氯仿和甲醇混合物)中反应,反应后过滤,滤液为芒果苷脂质体溶液(MF-Lip);所述的银纳米团簇的制备方法为,将50mmol/L硫辛酸甲醇溶液3mL,超纯水22mL,20mmol/L硝酸银溶液10mL,100mmol/L硼氢化钠溶液2mL,混合搅拌,反应3h,离心得到银纳米团簇(Ag NCs)。
将实施例1-5及对比例1-3得到的产品进行性能测试,测试结果如表1和表2所示。
表1产品抗菌测试结果
表1数据显示,实验例3和实验例4的产品Ag NCs@CH,当凝胶中银离子浓度相同时,壳聚糖溶液的浓度升高,导致凝胶网络致密,银的缓释变慢,因此杀菌性降低,故本发明发现壳聚糖的浓度为1%(w/v),Ag NCs@CH的杀菌效果最佳。实验例3和对比例1、2数据可知,单独的银纳米团簇、单独的壳聚糖杀菌性不高,当两者集成后,协同杀菌效果明显提高,这说明壳聚糖的吸附性将细菌吸附到水凝胶中,然后银纳米团簇释放杀菌物质(Ag+和活性氧基团),高效集成杀菌。通过对比例2和3,由于壳聚糖浓度升高,凝胶中的铵基变多,对于带负电的细菌的吸附性变大,杀菌性提高。
表2产品其他性能测试
表2数据显示,通过比较对比例2与实验例3的各项性能可知:当加入银纳米团簇后,壳聚糖水凝胶的杀菌性能显著提高,并且随着硫辛酸保护的团簇的加入,水凝胶的生物相容性得到改善,溶胀率提高;银纳米团簇的加入使水凝胶的亲水性增加,水分子在凝胶网络中运动增加,溶胀能力增强,细胞保护作用提升,但是溶胀率太高,会影响网络紧密性,在复杂的生物体内的产品的稳定性会受影响,力学性能也会受到影响,而本发明加入的芒果苷脂质体是疏水性物质,水分子运动受阻,使产品的孔隙率下降,溶胀率降低,如此本发明实施例5得到的产品的溶胀率达到最佳;同时,又因芒果苷的加入同时提高了凝胶的生物安全性,对细胞的毒性减少,并且抑制了细胞凋亡,通过记录不同天数大鼠伤口的愈合情况,如图4(a),发现与对照组相比,本发明能够较好促进伤口愈合,而且进一步通过第四天的大鼠组织切片发现,实施例5的水凝胶4天后的大鼠伤口未发生明显的炎症反应及坏死,并产生了新生的毛囊与毛细血管,详见大鼠伤口的切片观察图4(b)(圆形:炎症区域;直线:坏死区域;方框:新生毛囊;箭头:新生毛细血管)显示,而未处理的空白组出现炎症及坏死。
实施例5与实验例3相比可知:当在含银团簇的水凝胶中添加有效剂量的芒果苷后,水凝胶的杀菌率进一步提升,并且扩大到革兰氏阴性菌与革兰氏阳性菌的灭杀性测试,我们制备的产品,对枯草芽孢杆菌(B.subtilis)、大肠杆菌(E.coli)、铜绿假单胞菌(P.aeruginosa)和金黄色葡萄球菌(S.aureus)的杀菌率均达到99.99%,详见图5。
因此,本发明提供的壳聚糖水凝胶负载的银纳米团簇及芒果苷复合水凝胶,协同壳聚糖、银纳米团簇和芒果苷,具有高效广谱杀菌能力,促进组织修复再生能力,抗炎症及坏死,良好的生物相容性等多功能。
对实施例5得到的复合水凝胶Ag NCs@CH-MF的可注射性能进行测试,测试结果见图6。图6展示了Ag NCs@CH-MF水凝胶注射到玻璃板及水中的图片,由图可知,图6上为注射水凝胶的照片,图6下为注入水的水凝胶的图像,显示实施例5得到的水凝胶Ag NCs@CH-MF可注射,注射性好,且注入水中然后保持胶的形貌,如此可使其在各种复杂情况下的伤口治疗,发挥最大程度的杀菌和促进伤口愈合的作用。
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (6)
1.银纳米团簇基壳聚糖水凝胶敷料的制备方法,其特征在于:将银纳米团簇溶液(AgNC s)和芒果苷脂质体溶液(MF-Lip)混合搅拌,然后加入0.15-3 mL的 1%w/v壳聚糖溶液,0.1-3mL 的3%w/v聚乙二醇溶液,混合搅拌,最后加入0.01-0.3 mL的 2%w/v戊二醛搅拌5-200 min,停放30-180 min后成胶,得到Ag NCs@CH-MF水凝胶敷料;
所述银纳米团簇(Ag NCs)溶液和芒果苷脂质体溶液(MF-Lip)的总体积为0.01-3 mL;
所述银纳米团簇(Ag NCs)溶液的含银量为4.723 mg/L,所述芒果苷脂质体溶液(MF-Lip)中含有芒果苷量1-500 mg;
所述银纳米团簇的制备方法为,将50 mmol/L硫辛酸甲醇溶液1-5 mL,超纯水3.3-33mL,20 mmol/L硝酸银溶液0.2-20 mL,100 mmol/L硼氢化钠溶液0.05-5 mL,混合搅拌,反应3 h,离心得到银纳米团簇溶液(Ag NCs)。
2.如权利要求1所述的制备方法,其特征在于:所述1%w/v壳聚糖溶液是将1 g壳聚糖溶于100 mL的2%w/v乙酸溶液中加热溶解,然后加入氢氧化钠溶液中和得到的;所述壳聚糖为脱乙酰度为90%的壳聚糖。
3.如权利要求1所述的制备方法,其特征在于:所述芒果苷脂质体溶液的合成方法为,将4-20重量份卵磷脂,1-15重量份胆固醇,0.1-10重量份的芒果苷(MF)溶解在溶剂中反应,反应后过滤,滤液为芒果苷脂质体溶液(MF-Lip)。
4.如权利要求3所述的制备方法,其特征在于:所述溶剂为氯仿和甲醇混合物,所述氯仿和甲醇的体积比为1:1。
5.如权利要求1-4任一所述的制备方法制备的银纳米团簇基壳聚糖水凝胶敷料。
6.如权利要求5所述的银纳米团簇基壳聚糖水凝胶敷料在制备杀菌、抗炎症以及促进伤口愈合和组织修复再生复合材料中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010038788.0A CN111035801B (zh) | 2020-01-14 | 2020-01-14 | 银纳米团簇基壳聚糖水凝胶敷料及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010038788.0A CN111035801B (zh) | 2020-01-14 | 2020-01-14 | 银纳米团簇基壳聚糖水凝胶敷料及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111035801A CN111035801A (zh) | 2020-04-21 |
CN111035801B true CN111035801B (zh) | 2022-01-14 |
Family
ID=70244544
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010038788.0A Active CN111035801B (zh) | 2020-01-14 | 2020-01-14 | 银纳米团簇基壳聚糖水凝胶敷料及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111035801B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111739998A (zh) * | 2020-07-03 | 2020-10-02 | 青岛科技大学 | 一种基于银团簇的高显色性白光led及其制备方法 |
CN113072716A (zh) * | 2021-03-17 | 2021-07-06 | 武汉理工大学 | 一种光交联壳聚糖水凝胶的制备方法 |
CN113415994A (zh) * | 2021-06-02 | 2021-09-21 | 青岛科技大学 | 一种基于银纳米团簇的新型抗菌釉料 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008109887A1 (en) * | 2007-03-08 | 2008-09-12 | Biozone Laboratories Inc. | Dressing formulations to prevent and reduce scarring |
CN103480032A (zh) * | 2013-09-25 | 2014-01-01 | 南阳市汇博生物技术有限公司 | 一种含银复合凝胶敷料及其制备方法 |
CN104497345A (zh) * | 2015-01-06 | 2015-04-08 | 王健 | 一种透明质酸-壳聚糖可降解敷料的制备方法 |
CN105733032A (zh) * | 2016-02-26 | 2016-07-06 | 湖北大学 | 银纳米簇凝胶的制备方法及其应用 |
CN107501577A (zh) * | 2017-09-21 | 2017-12-22 | 天津工业大学 | 一种可降解原位凝胶的制备方法 |
CN109453197A (zh) * | 2018-12-20 | 2019-03-12 | 江苏经贸职业技术学院 | 一种基于银纳米簇与壳聚糖抗菌制剂的合成方法 |
CN109939260A (zh) * | 2019-03-01 | 2019-06-28 | 昆明理工大学 | 一种医用壳聚糖/透明质酸钠偶联水凝胶的制备方法 |
CN110448734A (zh) * | 2019-09-03 | 2019-11-15 | 深圳市第二人民医院 | 基于水凝胶和脂质体的复合载药递送材料的制备方法 |
CN110655651A (zh) * | 2019-10-12 | 2020-01-07 | 中国空气动力研究与发展中心高速空气动力研究所 | 一种硫辛酸-银纳米自修复材料及其制备方法、应用 |
-
2020
- 2020-01-14 CN CN202010038788.0A patent/CN111035801B/zh active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008109887A1 (en) * | 2007-03-08 | 2008-09-12 | Biozone Laboratories Inc. | Dressing formulations to prevent and reduce scarring |
CN103480032A (zh) * | 2013-09-25 | 2014-01-01 | 南阳市汇博生物技术有限公司 | 一种含银复合凝胶敷料及其制备方法 |
CN104497345A (zh) * | 2015-01-06 | 2015-04-08 | 王健 | 一种透明质酸-壳聚糖可降解敷料的制备方法 |
CN105733032A (zh) * | 2016-02-26 | 2016-07-06 | 湖北大学 | 银纳米簇凝胶的制备方法及其应用 |
CN107501577A (zh) * | 2017-09-21 | 2017-12-22 | 天津工业大学 | 一种可降解原位凝胶的制备方法 |
CN109453197A (zh) * | 2018-12-20 | 2019-03-12 | 江苏经贸职业技术学院 | 一种基于银纳米簇与壳聚糖抗菌制剂的合成方法 |
CN109939260A (zh) * | 2019-03-01 | 2019-06-28 | 昆明理工大学 | 一种医用壳聚糖/透明质酸钠偶联水凝胶的制备方法 |
CN110448734A (zh) * | 2019-09-03 | 2019-11-15 | 深圳市第二人民医院 | 基于水凝胶和脂质体的复合载药递送材料的制备方法 |
CN110655651A (zh) * | 2019-10-12 | 2020-01-07 | 中国空气动力研究与发展中心高速空气动力研究所 | 一种硫辛酸-银纳米自修复材料及其制备方法、应用 |
Also Published As
Publication number | Publication date |
---|---|
CN111035801A (zh) | 2020-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ahmed et al. | In-vitro and in-vivo study of superabsorbent PVA/Starch/g-C3N4/Ag@ TiO2 NPs hydrogel membranes for wound dressing | |
CN110354295B (zh) | 一种光热转换材料及其制备方法 | |
Namazi et al. | Antibiotic loaded carboxymethylcellulose/MCM-41 nanocomposite hydrogel films as potential wound dressing | |
Zhao et al. | Gold@ Halloysite nanotubes-chitin composite hydrogel with antibacterial and hemostatic activity for wound healing | |
Varaprasad et al. | Alginate-based composite materials for wound dressing application: A mini review | |
Zhang et al. | Electrospun fibrous mat based on silver (I) metal-organic frameworks-polylactic acid for bacterial killing and antibiotic-free wound dressing | |
CN111035801B (zh) | 银纳米团簇基壳聚糖水凝胶敷料及其制备方法和应用 | |
Yuan et al. | Nano-silver functionalized polysaccharides as a platform for wound dressings: A review | |
Wang et al. | Hydrogel sheets of chitosan, honey and gelatin as burn wound dressings | |
Aramwit et al. | The characteristics of bacterial nanocellulose gel releasing silk sericin for facial treatment | |
You et al. | Together is better: poly (tannic acid) nanorods functionalized polysaccharide hydrogels for diabetic wound healing | |
Naghshineh et al. | Preparation of chitosan, sodium alginate, gelatin and collagen biodegradable sponge composites and their application in wound healing and curcumin delivery | |
He et al. | Bacterial cellulose: functional modification and wound healing applications | |
Liberman et al. | Antimicrobial hydrogels composed of chitosan and sulfated polysaccharides of red microalgae | |
CN107141345B (zh) | 一种角蛋白生物大分子一氧化氮供体及其合成与应用 | |
Wei et al. | Quaternized chitosan/cellulose composites as enhanced hemostatic and antibacterial sponges for wound healing | |
Lin et al. | Dressing with epigallocatechin gallate nanoparticles for wound regeneration | |
Liu et al. | A simultaneous grafting/vinyl polymerization process generates a polycationic surface for enhanced antibacterial activity of bacterial cellulose | |
Huang et al. | Preparation of novel stable microbicidal hydrogel films as potential wound dressing | |
AU2021100755A4 (en) | Silver Nanocluster-based Chitosan Hydrogel Dressing and Its Preparation Method and Application | |
CN106146862A (zh) | 一种抗菌性的超分子杂合水凝胶及其制备方法和应用 | |
Rostami et al. | Evaluation of application of chitosan/nano selenium biodegradable film on full thickness excisional wound healing in rats | |
Municoy et al. | Tuning the antimicrobial activity of collagen biomaterials through a liposomal approach | |
Li et al. | Synergic fabrication of titanium dioxide incorporation into heparin-polyvinyl alcohol nanocomposite: enhanced in vitro antibacterial activity and care of in vivo burn injury | |
Liu et al. | Physicochemical properties and antibacterial activity of gellan gum incorporating zinc oxide/carbon nanotubes bionanocomposite film for wound healing |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |